Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Neal Shore, MD, FACS, discusses sasanlimab and its potential impact for community oncologists when treating patients with ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

A transformative milestone in cancer care has arrived in Central New Jersey with the reopening of the John Theurer Cancer ...

Jason M. Hafron, MD, discusses IsoPSA, a novel prostate-specific antigen assay for patients with a PSA > 4ng/ml who are ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Sofia Chernoff, PsyD, MSEd, discussed how cognitive behavioral therapy helps cancer patients manage emotional challenges by ...

A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting ...

Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ...

An expert discusses how treatment selection in blastic plasmacytoid dendritic cell neoplasm (BPDCN) involves balancing ...

INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.